As mutations in p53 are extremely frequent in ovarian cancer and can impact disease progression and therapeutic response, it is critical to determine if the p53-status of the tumor cells influences the observed oncogenic effects of ZNF217 overexpression19,20,34. This evidence concerns the gene ZNF217 and neoplasm.